ADMA Biologics, Inc. (NASDAQ:ADMA) Director Sells $3,941,719.76 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director now directly owns 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Steve Elms also recently made the following trade(s):

• On Thursday, June 12th, Steve Elms sold 92,941 shares of ADMA Biologics stock. The stock was sold at an average price of $21.69, for a total transaction of $2,015,890.29.
• On Friday, June 13th, Steve Elms sold 137,931 shares of ADMA Biologics stock. The stock was sold at an average price of $20.82, for a total transaction of $2,871,723.42.

ADMA Biologics Trading Down 2.0%

NASDAQ ADMA opened at $20.40 on Tuesday. ADMA Biologics, Inc. has a one year low of $10.21 and a one year high of $25.67. The company's 50 day moving average price is $20.99 and its 200 day moving average price is $18.83. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $4.87 billion, a price-to-earnings ratio of 72.86 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same quarter in the previous year, the business posted $0.08 EPS. The company's quarterly revenue was up 40.2% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on ADMA. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of ADMA Biologics by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock valued at $312,109,000 after purchasing an additional 80,302 shares during the period. Invesco Ltd. raised its stake in shares of ADMA Biologics by 13.9% during the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock valued at $255,279,000 after purchasing an additional 1,570,649 shares during the period. Geode Capital Management LLC raised its stake in shares of ADMA Biologics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock valued at $93,187,000 after purchasing an additional 50,399 shares during the period. Nuveen LLC purchased a new stake in shares of ADMA Biologics during the first quarter valued at approximately $93,543,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after purchasing an additional 643,661 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.